Víctor Granados-García1, Yvonne N Flores1, Ruth Pérez2, Samantha E Rudolph1, Eduardo Lazcano-Ponce3, Jorge Salmerón1. 1. Unidad de Investigación Epidemiológica y en Sistemas de Salud, Área de envejecimiento, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México, Distrito Federal, México. 2. Coordinación Delegacional de Abastecimiento y Equipamiento, Delegación Morelos, Instituto Mexicano del Seguro Social, México, Distrito Federal, México. 3. Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Abstract
OBJECTIVE: To estimate the annual cost of the National Cervical Cancer Screening Program (CCSP) of the Mexican Institute of Social Security (IMSS). MATERIALS AND METHODS: This cost analysis examined regional coverage rates reported by IMSS. We estimated the number of cytology, colposcopy, biopsy and pathology evaluations, as well as the diagnostic test and treatment costs for cervical intraepithelial neoplasia grade II and III (CIN 2/3) and cervical cancer. Diagnostic test costs were estimated using a micro-costing technique. Sensitivity analyses were performed. RESULTS: The cost to perform 2.7 million cytology tests was nearly 38 million dollars, which represents 26.1% of the total program cost (145.4 million). False negatives account for nearly 43% of the program costs. CONCLUSION: The low sensitivity of the cytology test generates high rates of false negatives, which results in high institutional costs from the treatment of undetected cervical cancer cases.
OBJECTIVE: To estimate the annual cost of the National Cervical Cancer Screening Program (CCSP) of the Mexican Institute of Social Security (IMSS). MATERIALS AND METHODS: This cost analysis examined regional coverage rates reported by IMSS. We estimated the number of cytology, colposcopy, biopsy and pathology evaluations, as well as the diagnostic test and treatment costs for cervical intraepithelial neoplasia grade II and III (CIN 2/3) and cervical cancer. Diagnostic test costs were estimated using a micro-costing technique. Sensitivity analyses were performed. RESULTS: The cost to perform 2.7 million cytology tests was nearly 38 million dollars, which represents 26.1% of the total program cost (145.4 million). False negatives account for nearly 43% of the program costs. CONCLUSION: The low sensitivity of the cytology test generates high rates of false negatives, which results in high institutional costs from the treatment of undetected cervical cancer cases.
Authors: Juan Ramón Padilla-Mendoza; Lucía Angélica Gómez-López; Mavil López-Casamichana; Elisa Irene Azuara-Liceaga; Enoc Mariano Cortés-Malagón; Lilia López-Cánovas; Octavio Daniel Reyes-Hernández; Mario Alberto Rodríguez; José Bonilla-Delgado; Israel López-Reyes Journal: Biomed Res Int Date: 2020-11-13 Impact factor: 3.411
Authors: Juan Ramón Padilla-Mendoza; Arturo Contis-Montes de Oca; Mario Alberto Rodríguez; Mavil López-Casamichana; Jeni Bolaños; Laura Itzel Quintas-Granados; Octavio Daniel Reyes-Hernández; Fabiola Fragozo-Sandoval; Aldo Arturo Reséndiz-Albor; Claudia Vanessa Arellano-Gutiérrez; Israel López-Reyes Journal: Biomed Res Int Date: 2020-04-02 Impact factor: 3.411